Pharmaceutical News

RSS

Contraceptive pill prevents loss of eye sight

Scientists at University College Cork (UCC) have shown that the active component (Norgestrel) of the contraceptive 'Mini Pill' prevents the loss of sight in mice that have degenerative eye conditions that normally lead to blindness.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

Short-term glucocorticoid treatment may prevent osteoarthritis after joint injury

Joint injury can result in irreversible damage of cartilage which, despite treatment and surgery, often eventually leads to osteoarthritis (OA) in later life. New research published in BioMed Central's open access journal Arthritis Research & Therapy demonstrates that short term treatment of damaged cartilage with glucocorticoids can reduce long term degenerative changes and may provide hope for prevention of OA after injury.

2 Sep 2011

'Sustainable global pharmacovigilance' systems needed to monitor ARVs, other drugs

With more widespread access to antiretroviral (ARV) drugs comes a greater need to monitor and promote the safety and effectiveness of these essential medicines in the new environments, which are distinct from those of pre-market studies and the resource rich countries that have had ARV access for years.

2 Sep 2011

UC Davis computer model can test effects of anti-arrhythmia medications

UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

2 Sep 2011

FTC presses for more competition on generic drugs

Some drug makers are using an indirect method to delay competition from low-cost generic products by promising not to introduce their own generic versions if a potential competitor delays its entry into the market, the Federal Trade Commission said in a report on Wednesday.

2 Sep 2011

Ancient antibiotic resistance findings leads experts to stress need to use antibiotics sparingly

"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.

2 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

Dendritic cells play central role in regulation of acetaminophen's toxicity

NYU School of Medicine researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.

2 Sep 2011

Stomach acid-reducing drugs appear to cause small intestine damage

Patients often take drugs to lower stomach acid and reduce the chances they will develop ulcers from taking their anti-inflammatory drugs for conditions such as arthritis, but the combination may be causing major problems for their small intestines, McMaster researchers have found.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

FDA may be allowed an extra 2 months to review new drugs

The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.

2 Sep 2011

Study reveals how pharmaceutical managers can maximize the return on marketing investments

Research in Marketing Science by Professor Kamel Jedidi, John A. Howard Professor of Business, Marketing, Columbia Business School; Professor Oded Netzer, Philip H. Geier Jr. Associate Professor, Marketing, Columbia Business School; and Professor Ricardo Montoya, Department of Industrial Engineering, University of Chile, Santiago, Chile, reveals how pharmaceutical managers can maximize the return on marketing investments - by determining the physicians to target as well as when and how to target them.

31 Aug 2011

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.

31 Aug 2011

Research shows numerous health benefits of Modified Citrus Pectin

New research published in the journal BMC Complementary and Alternative Medicine shows Modified Citrus Pectin (MCP) packs a powerful immune punch.

31 Aug 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

More and more, patients show up to appointments with hypertension expert John Bisognano, M.D., Ph.D. carrying bags full of "natural" products that they hope will help lower their blood pressure. And like most physicians, Bisognano doesn't always know if these products will do any good, or if they will cause any harm.

31 Aug 2011

Cost of second-line ARVs a 'huge barrier to care' in resource-poor countries

In this U.N. Dispatch blog post, Mark Leon Goldberg, managing editor of the blog, examines the costs of second-line antiretroviral treatments (ARVs), which "are several orders of magnitude more expensive than traditional, first-line ARV treatments" and are a "huge barrier to providing care" for resource-poor countries.

31 Aug 2011

Insight Pharmaceuticals announces acquisition of MONISTAT business from McNEIL-PPC

Insight Pharmaceuticals, a portfolio company of Swander Pace Capital, announced today that it has acquired the MONISTAT North American brand portfolio from McNEIL-PPC, Inc.

31 Aug 2011

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.

31 Aug 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

Pharmaceutical News

Contraceptive pill prevents loss of eye sight

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Short-term glucocorticoid treatment may prevent osteoarthritis after joint injury

'Sustainable global pharmacovigilance' systems needed to monitor ARVs, other drugs

UC Davis computer model can test effects of anti-arrhythmia medications

FTC presses for more competition on generic drugs

Ancient antibiotic resistance findings leads experts to stress need to use antibiotics sparingly

FDA approves crizotinib for treatment of ALK-positive lung cancer

Dendritic cells play central role in regulation of acetaminophen's toxicity

Stomach acid-reducing drugs appear to cause small intestine damage

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

FDA may be allowed an extra 2 months to review new drugs

Study reveals how pharmaceutical managers can maximize the return on marketing investments

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Research shows numerous health benefits of Modified Citrus Pectin

Comprehensive review on non-drug interventions for treatment of high blood pressure

Cost of second-line ARVs a 'huge barrier to care' in resource-poor countries

Insight Pharmaceuticals announces acquisition of MONISTAT business from McNEIL-PPC

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News